Over the past few years, China and India have been the up-and-coming destinations for international outsourcing of biopharmaceutical
manufacturing. Last year, industry research pointed to China and India as the industry's top potential destinations for offshoring
over the next five years, which put them ahead of traditional biomanufacturing hubs in the US and Western Europe. China was
seen as a favorite likely destination for both US and European respondents to prior studies, with India close behind.
In BioPlan Associates' 10th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production, however, that initial enthusiasm appears to have diminished (1). Of the more than 25 countries identified as potential destinations
for international outsourcing, India fell to the fourth spot among all respondents, with only 14% of respondents indicating
there was a likelihood or strong likelihood that they would consider outsourcing production there in the next five years.
Surprisingly, that was a more positive result than for China, which was cited by just 10.6% of respondents, putting it in
the ninth spot, behind countries such as Austria and Australia.
This year, the US took the top position for biopharmaceutical outsourcing, with 26.3% of global, non-US respondents, ranking
it as the top destination. This ranking likely reflects European companies' plans, as respondents were asked to indicate potential
international destinations (see Figure 1). Next on the list were Germany and Singapore, each indicated to be a "likelihood" destination by 15.8% of all respondents.
Beyond those top three countries stood a group of countries (India, UK, Austria, and Ireland), each receiving the nod from
approximately 14% of respondents.
Figure 1: Destinations for international outsourcing of biomanufacturing (all respondents). (ALL FIGURES ARE COURTESY OF THE